Objective: The present research aimed to investigate whether a pharmacokinetic drug interaction exists between atomoxetine, a substrate of CYP2D6 and duloxetine, an enzymatic inhibitor of the same metabolic pathway.
Methods: Twenty-three healthy volunteers were enrolled in an open-label, non-randomized, sequential, 2-period clinical study. During the trial, they received a single dose of atomoxetine 25 mg (Period 1:Reference) followed by a combination of atomoxetine 25 mg and duloxetine 30 mg, after a pretreatment regimen with duloxetine 30-60 mg/day for 4 days (Period 2:Test). The pharmacokinetic parameters of atomoxetine and its main metabolite (4-hydroxyatomoxetine-O-glucuronide) were estimated using a non-compartmental approach and statistical tests were used to compare these parameters between study periods.
Results: A total of 22 subjects, extensive metabolizers (EMs), were considered for the final report of the study findings. Duloxetine influenced the plasma concentration-time profile of both parent drug and its glucuronidated metabolite. The pharmacokinetic and statistical analysis revealed that pretreatment with the enzymatic inhibitor increased the mean atomoxetine AUC0–t (from 1151.19±686.52 to 1495.54±812.40 [ng*h/mL]) and AUC0–∞ (from 1229.15±751.04 to 1619.37±955.01 [ng*h/mL]) while kel was decreased and the mean t1/2 was prolonged. With regard to 4-hydroxyatomoxetine-O-glucuronide, Cmax was reduced from 688.76±270.27 to 621.60±248.82 [ng/mL] after coadministration of atomoxetine and duloxetine.
Conclusions: Duloxetine had an impact on the pharmacokinetics of atomoxetine as it increased the exposure to the latter by ~30%. Although the magnitude of this pharmacokinetic interaction is rather small, a potential clinical relevance cannot be ruled out with certainty without further investigation.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Corman SL Fedutes BA Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm. 2004;61(22):2391–9.
2. Barton J. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. Arch Dis Child. 2005;90 Suppl 1:i26-9.
3. Sauer J-M Ring BJ Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571–90.
4. Ring BJ Gillespie JS Eckstein JA Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos. 2002 ;30(3):319–23.
5. Yu G Li G-F Markowitz JS. Atomoxetine: A review of its pharmacokinetics and pharmacogenomics relative to drug disposition. J Child Adolesc Psychopharmacol. 2016;26(4):314-26.
6. Knadler MP Lobo E Chappell J Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2011;50(5):281–94.
7. Wernicke JF Gahimer J Yalcin I Wulster-radcliffe M Viktrup L. Safety and adverse event profile of duloxetine. Expert Opin Drug Saf. 2005;4(6):987-93.
8. Carter NJ McCormack PL. Duloxetine: A review of its use in the treatment of generalized anxiety disorder. CNS Drugs. 2009;23(6):523–41.
9. Sobanski E Paslakis G Schredl M et al. Managing ADHD in adults with common comorbidities. In: Surman C ed. ADHD in adults. A practical guide to evaluation and managament. Current Clinical Psychiatry. Totowa NJ: Humana Press; 2013. p. 137–54.
10. Bond DJ Hadjipavlou G Lam RW et al. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry. 2012;24(1):23–37.
11. Kooij JJS Bijlenga D Salerno L et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019;56:14–34.
12. Dodangi N Habibi N Astaneh AN. Preliminary investigation on duloxetine efficacy in the treatment of children with attention-deficit hyperactivity disorder. J Compr Pediatr. 2015; 6(4):e27482. doi: 10.17795/compreped-27482.
13. Niederhofer H. Duloxetine may improve some symptoms of attention-deficit/hyperactivity disorder. Prim Care Companion J Clin Psychiatry. 2010;12(2): PCC.09l00807. doi: 10.4088/PCC.09l00807pin.
14. Faul F Erdfelder E Lang AG Buchner A. G*Power 3: A flexible statistical power analysis program for the social behavioral and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.
15. Todor I Popa A Neag M et al. Evaluation of the potential pharmacokinetic interaction between atomoxetine and fluvoxamine in healthy volunteers. Pharmacology. 2017;99(1-2):84-88.
16. Todor I Popa A Neag M et al. Evaluation of a potential metabolism-mediated drug-drug interaction between atomoxetine and bupropion in healthy volunteers. J Pharm Pharm Sci. 2016;19(2):198–207.
17. Todor I Popa A Neag M et al. The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. Clujul Med. 2015;88(4):513-520.
18. Thapar A Cooper M. Attention deficit hyperactivity disorder. Lancet.2015;387(10024):1240–50.
19. Biederman J Petty CR Evans M Small J Faraone S V. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res. 2010;177(3):299–304.
20. Faraone S V Biederman J Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159–65.
21. Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9(3):490–9.
22. Fayyad J De Graaf R Kessler R et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402–9.
23. Wang B Yang L-P Zhang XZ Huang SQ Bartlam M Zhou SF. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev. 2009;41(4):573–643.
24. Lin ND Norman H Regev A et al. Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a US health care claims database. BMC Gastroenterol. 2015; 15:134. doi: 10.1186/s12876-015-0373-4.
25. Belle DJ Ernest CS Sauer J Smith BP Thomasson HR Witcher JW. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol. 2002;42(11):1219-27.
26. Childress AC. A critical appraisal of atomoxetine in the management of ADHD. Ther Clin Risk Manag. 2015; 12:27-39.
27. Fredriksen M Halmøy A Faraone S V Haavik J. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD : A review of controlled and naturalistic studies. Eur Neuropsychopharmacol. 2013;23(6):508-27.
28. Hennissen L Bakker MJ Banaschewski T et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD : a systematic review and meta-analysis of trials of methylphenidate amphetamines and atomoxetine. CNS Drugs. 2017;31(3):199–215.
29. Kasi PM Mounzer R Gleeson GH. Cardiovascular side effects of atomoxetine and its interactions with inhibitors of the cytochrome p450 system. Case Rep Med. 2011;2011:952584. doi: 10.1155/2011/952584.